The Discovery
A Mystery in the Stomach
In 1998, researchers weren't looking for a heart medicine.
Key moment
Then Masahiko Fujino and Katsutoshi Tatemoto found it: an unknown peptide.
In 1998, researchers weren't looking for a heart medicine. They were studying bovine stomach tissue searching for something else entirely. Then Masahiko Fujino and Katsutoshi Tatemoto found it: an unknown peptide. They called it apelin because they weren't sure what it was. It seemed ordinary at first—just another chemical in tissue samples. But this ordinary peptide had extraordinary powers. The team realized it was special, but they didn't yet know just how special. Nature had hidden a treasure in the last place anyone thought to look.
The Breakthrough
Finding the Missing Lock
Scientists had discovered a strange receptor called APJ years earlier.
Key moment
Scientists had discovered a strange receptor called APJ years earlier.
Scientists had discovered a strange receptor called APJ years earlier. APJ was an orphan—a receptor with no known job. It sat on heart and blood vessel cells waiting for something to talk to it. For years, nobody knew what APJ did. Then the pieces clicked together. Apelin was APJ's perfect partner. When apelin found APJ and attached, everything changed. Scientists realized APJ wasn't useless. It was APJ for 'Apelin-Putative-J-receptor.' Apelin was the missing voice that APJ had been waiting to hear.
The Trials
The Strongest of Its Kind
The apelin peptide family has many versions.
Key moment
In one peptide, they found the most effective version of a family of helpers.
The apelin peptide family has many versions. Some have 12 amino acids. Some have 36. But apelin-13—the 13 amino acid version—is the strongest. It packs the most punch into the smallest package. When apelin-13 grabbed APJ, hearts woke up. Weak pumps started pumping harder. Blood flow improved. Tired hearts felt energized. Scientists tested apelin-13 against other forms and the results were clear. It was the champion. It worked faster. It worked stronger. It worked better. In one peptide, they found the most effective version of a family of helpers.
The Crisis
The Regeneration Discovery
As research deepened, scientists discovered apelin-13 did more than just boost pumping.
Key moment
As research deepened, scientists discovered apelin-13 did more than just boost pumping.
As research deepened, scientists discovered apelin-13 did more than just boost pumping. It helped hearts grow new blood vessels around scarred areas. After a heart attack, scar tissue blocks blood flow to healthy muscle. Apelin-13 commanded the body to create new routes. Blood could now reach previously starved tissue. Damaged areas could heal. This wasn't just temporary help. It was permanent repair. It was like building new roads around a traffic jam instead of just telling cars to drive faster. Apelin-13 showed that damaged hearts could regenerate with the right help.
The Legacy
The Future of Heart Healing
Today apelin-13 is in clinical trials for heart failure and pulmonary hypertension.
Key moment
The peptide discovered in cow stomach tissue is becoming one of the most important discoveries in cardiology.
Today apelin-13 is in clinical trials for heart failure and pulmonary hypertension. Early results show promise beyond imagination. Some patients with severe symptoms improve dramatically. Hospitals are excited. Researchers are expanding studies. The question is no longer whether apelin-13 works but how many patients it can help. The peptide discovered in cow stomach tissue is becoming one of the most important discoveries in cardiology. From a chance finding to a hope for millions. Apelin-13 shows that sometimes the answer to our biggest problems comes from looking where we've never looked before.
Peptide history · 1998
Apelin Peptide 13-Amino Acid Form
The heart-strengthening peptide discovered in cow stomachs that could revolutionize heart failure treatment
Apelin-13 is a 13 amino acid peptide that powers up your heart's pumping strength. First discovered in 1998 from bovine stomach tissue, it was originally searching for a home until scientists found its receptor APJ. Now this remarkable peptide shows promise for treating heart failure and helping damaged hearts heal.
When this peptide was first identified
Compound classification
Current regulatory status
Main area of investigation
How this peptide is typically given
Molecular structure type
Masahiko Fujino
Takeda Chemical Industries, Japan
Co-discovered apelin at Gunma University
Katsutoshi Tatemoto
Karolinska Institute, Stockholm, Sweden
Led the team that identified apelin as APJ receptor ligand
Takeda Pharmaceutical Team
Takeda Pharmaceutical Company, Osaka, Japan
Collaborated on initial apelin characterization studies
13 milestones, 1993 – 2024.
- 1993APJ receptor first identified as mysterious protein on heart cells
- 1998Apelin discovered in bovine stomach tissue by Fujino and colleagues
- 1998Apelin identified as the ligand that activates APJ receptor
- 2000Apelin-13 confirmed as the strongest bioactive form
- 2005Studies show apelin-13 strengthens heart pumping in animal models
- 2010Discovery of apelin-13 effects on new blood vessel growth
- 2012First human trials begin for heart failure patients
- 2016Apelin-13 shows promise for pulmonary hypertension treatment
- 2019Studies reveal heart regeneration potential after damage
- 2021Phase 2 clinical trials expand significantly
- 2022Research shows synergy with other heart medications
- 2023Long-term safety data supports continued development
- 2024Multiple pharmaceutical companies advancing apelin-13 candidates
Apelin-13 is your heart's personal trainer. It finds the APJ sensor on heart muscle cells and tells them to contract harder. It also whispers to blood vessel cells to grow new pathways. Think of your heart like a tired athlete. Apelin-13 doesn't make it run laps—it teaches it to run better laps. Your heart was made to respond to apelin. All you're doing is giving it more of what it already needs. The result? A stronger pump. Better blood flow. Healthier tissue. Your own heart healing itself.
Molecular structure
- Amino Acid Count
- 13 amino acids
- Molecular Weight
- 1,550.8 Daltons
- Primary Source
- Pre-pro-apelin protein
- Primary Sensor
- APJ receptor
Real stories, real lives
Robert's Story
Robert was told he might need a heart transplant. His heart was barely pumping. Walking to the mailbox left him breathless. Doctors enrolled him in an apelin-13 trial as a last-ditch effort. Within weeks, something shifted. His heart started pumping harder. He could walk without stopping. He climbed stairs for the first time in years. His wife cried when she saw him play with grandchildren. Robert's heart scans improved so much his doctors said transplant might not be necessary. He tells everyone: apelin-13 gave him his life back.
Patricia's Story
Patricia's heart attack left permanent damage. Scar tissue killed healthy muscle. She felt condemned to a limited life. Then she heard about apelin-13 research and joined a trial. Doctors explained it would help her heart grow new blood vessels around the scarred area. Patricia didn't expect much. But something remarkable happened. Her energy returned. Her shortness of breath improved dramatically. Scans showed new blood vessels had formed. Patricia now does water aerobics three times a week. She credits apelin-13 with giving her back the ability to live fully.
The future of Apelin-13
- Heart Attack RecoveryResearch Stage
Giving apelin-13 immediately after a heart attack might limit scar damage and speed healing. Trials are exploring this aggressive early-use strategy.
- Combination TherapiesResearch Stage
Apelin-13 works better when combined with standard heart medicines. Research is finding the optimal combinations.
- Pulmonary Hypertension TreatmentResearch Stage
High blood pressure in the lungs is deadly. Apelin-13 relaxes lung blood vessels and reduces pressure. This could be game-changing for patients with few options.
Be inspired
The story of Apelin-13 is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.